Medicare’s cost-help page now sends beneficiaries shopping for a better prescription price to TrumpRx.gov, a federal website built to surface the lowest cash price on certain drugs at the pharmacy counter. The referral is recent enough that many beneficiaries still assume any discount that shrinks a receipt must also move them closer to their plan’s yearly limits. It does not. Medicare treats a TrumpRx purchase much like a drugstore loyalty coupon: real money saved at checkout, but money that never enters the plan’s own ledger of what a person has paid toward Part D.
A Federal Discount Site That Sits Outside Part D
TrumpRx operates as a price-comparison and coupon tool rather than as a drug plan or a supplemental policy. It connects beneficiaries with special offers and the lowest cash prices on certain prescription drugs, then lets them print or download a coupon to use directly at checkout. Nobody buys medication from TrumpRx itself; the transaction still happens at the pharmacy, with the coupon substituting for whatever a Part D plan would otherwise charge that day. That structure is what keeps TrumpRx outside the bookkeeping Medicare uses for the Part D benefit, since the purchase never routes through a plan’s claims system at all.
Medicare has been explicit that a TrumpRx purchase, like other discount cards used instead of a Medicare drug plan, is not considered creditable coverage and does not count toward a beneficiary’s deductible or out-of-pocket maximum. Creditable coverage is the term Medicare uses for drug coverage that counts as good enough to satisfy Part D enrollment rules and, separately, to feed a beneficiary’s running totals under a Part D plan. A coupon that never touches creditable coverage cannot add anything to those totals, no matter how large the discount at the register.
Not every new access point Medicare rolled out for 2027 carries the same caveat. Medicare GLP-1 Bridge, introduced in the same round of program changes, gives people already enrolled in a Part D plan access to certain weight-loss drugs for a flat $50 monthly copayment when those drugs are not already covered. That program works through Part D rather than around it, which is why its copayment can count toward a beneficiary’s totals while a TrumpRx coupon, filed outside any plan, cannot.
Free download: What to ask the plan, the prescriber and the pharmacy, when to request an exception, and which records to keep. Download the free prescription coverage checklist.
Why the Deductible and the Out-of-Pocket Cap Still Move Without It
Part D’s own numbers are what make the exclusion consequential. No Medicare drug plan may charge a deductible above $700 in 2027, up from a $615 ceiling in 2026, and some plans charge less or nothing at all. Once a beneficiary clears that deductible, standard coverage moves into an initial-coverage stage in which the plan and the beneficiary split the cost of each prescription until total out-of-pocket spending on covered drugs reaches $2,100 in 2026 or $2,400 in 2027. Crossing that line triggers catastrophic coverage, the point at which covered drugs stop costing anything for the remainder of the calendar year.
None of that spending clock moves for a purchase made through TrumpRx. Medicare’s cost page notes that certain payments made on a beneficiary’s behalf, such as through the Extra Help program, do count toward the out-of-pocket threshold, which draws a sharp line between assistance that is formally built into Part D and a cash-price tool that sits beside it. A beneficiary filling a brand-name prescription every month through TrumpRx could pay less out of pocket all year than a plan’s own copay and still arrive at January no closer to the deductible or the catastrophic-coverage line than when the year began.
The distinction is not trivial for anyone managing a chronic prescription list. A beneficiary who pays a full $700 deductible out of pocket in 2027 is $700 closer to catastrophic coverage than one who paid nothing that year because a discount tool covered every fill outside the plan. TrumpRx does not shrink anyone’s ultimate protection under Part D, but it does mean that protection arrives later in the year, if it arrives at all, for anyone leaning on the site instead of filling through a plan.
A Second Discount Tool Carries the Same Warning
TrumpRx is not the only Medicare-adjacent option built around a similar catch. The Medicare Prescription Payment Plan, which lets a beneficiary spread a year of drug costs into monthly installments billed by the plan instead of paid at the pharmacy, carries an almost identical warning in Medicare’s own description: it can even out monthly expenses, but it does not save money or lower drug costs. Between the two programs, Medicare is effectively telling beneficiaries that convenience and cash savings are both available, but neither substitutes for the accounting that determines when catastrophic coverage begins.
The gap shows up clearly when two beneficiaries are compared side by side. One fills a brand-name prescription every month through a Part D plan and slowly climbs toward the $2,400 threshold with every claim; the other fills the identical prescription every month using a TrumpRx coupon and, regardless of how many discounted fills accumulate, never moves an inch closer to that line. Their bank statements might look similar by December, but only one of them is a single bad diagnosis away from catastrophic coverage kicking in.
That gap is unlikely to close on its own, because it stems from a legal distinction between creditable Part D coverage and outside discount arrangements rather than from any technical fix Medicare has proposed. Beneficiaries who split their prescriptions between a Part D plan and a cash-price tool such as TrumpRx are, in effect, keeping two separate ledgers, only one of which feeds the deductible and out-of-pocket figures Medicare publishes each year.
Medicare’s own fact sheet on 2027 program changes, published under CMS Product No. 12229, states the boundary in a single sentence: using TrumpRx or a similar discount card instead of Medicare or other coverage means it is not considered creditable coverage and does not count toward the deductible or the out-of-pocket maximum. For a beneficiary weighing whether to fill a prescription through a plan or through a cash-price coupon, that sentence is the entire calculation, regardless of which option produces the smaller number at the register.
What Counts Toward the Part D Out-of-Pocket Cap
The line between a cash-price discount and coverage that actually counts toward Part D’s limits is not something a pharmacy receipt spells out, and the deductible and out-of-pocket threshold involved keep moving from one plan year to the next. Beneficiaries who split prescriptions between a plan and a discount tool rarely have one place that tracks which dollars are counting toward their limit and which steps apply when a plan denies a covered alternative.
The Medicare Cost & Coverage Protection Kit is a 10-page kit that walks through the new Part D out-of-pocket cap and the prior-authorization appeal steps for challenging a plan’s denial, plus a medication and cost tracker built in.
See the current Part D out-of-pocket cap and the appeal steps in The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
